Select a community
MS
Find out more about the PatientsLikeMe
MS Community
Home > Community Treatment Reports > Lioresal Intrathecal (baclofen intrathecal) Treatment Report
What is Lioresal Intrathecal?

Lioresal is the brand name for the intrathecal formulation of baclofen, a muscle relaxer and an antispastic agent. Intrathecal administration is used for the treatment of intractable spasticity caused by spinal cord injury, multiple sclerosis, and other spinal disease.

Reasons taken & Efficacy

Reasons and Efficacy
Reasons taken # of patients Major Moderate Slight None Can’t tell # of patients evaluated by
Stiffness/Spasticity 6 0
Muscle cramping, spasms 2 1

Mouse over the table for more information

Side Effects

Side effects as an overall problem

Severe
0 0%
Moderate
0 0%
Mild
0 0%
None
1 100%

Dosages

  0.05 mg daily 0.5 mg/mL daily 30 mg daily 40 mg daily 100 mg daily
  1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1  

Stop Reasons

Why Patients Stopped Taking Lioresal Intrathecal (multiple reasons could be selected)
Reason # Patients Percentage of patients
Did not seem to work
1 33% Did not seem to work: 33%
Personal research
1 33% Personal research: 33%
Other
1 33% Other: 33%

See all 3 patients who’ve stopped taking Lioresal Intrathecal

Currently Taking Lioresal Intrathecal

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
1
0
1

Stopped Taking Lioresal Intrathecal

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
2
1
0

Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Always
1 100%
Usually
0 0%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Very
0 0%
Somewhat
1 100%
A little
0 0%
Not at all
0 0%

Cost

Paid out of pocket

$200+
1 100%
$100-199
0 0%
$50-99
0 0%
$25-49
0 0%
< $25
0 0%

See more information, including instructions, precautions, side effects, and interactions.

Report created on November 21, 2009.